Sarcoma Clinical Trial
Official title:
An Open-Label, Multicenter, First-in-Human, Phase 1 Dose-Escalation and Multicohort Expansion Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
This is a first-in-human, open-label, non-randomized, three-part phase 1 trial of INBRX-109, which is a recombinant humanized tetravalent antibody targeting the human death receptor 5 (DR5).
Status | Recruiting |
Enrollment | 240 |
Est. completion date | July 2026 |
Est. primary completion date | December 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 12 Years to 85 Years |
Eligibility | Inclusion Criteria: - Males or females aged =12 to <85 years for Ewing sarcoma and 18 to <85 years of age for GIST. - Escalation: Histologically or cytologically-confirmed advanced/metastatic or non-resectable solid tumors, including sarcoma, that are refractory or intolerant to standard therapy, or for which no standard therapy exists that is likely to confer any clinical benefit. - Expansion Cohorts: Malignant pleural mesothelioma, gastric adenocarcinoma, colorectal adenocarcinoma, pancreatic adenocarcinoma and certain sarcoma subtypes (e.g., chondrosarcoma, Ewing sarcoma), GIST, and SDH-def solid tumors with locally advanced or metastatic, non-resectable disease, that are refractory or intolerant to standard therapy, or for which no standard therapy exists that is likely to confer any clinical benefit. - Measurable disease as defined by RECISTv1.1 (or modified RECIST for mesothelioma) criteria. - Adequate hematologic, coagulation, hepatic and renal function as defined per protocol. - Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1 for Part 1 and ECOG PS of 0, 1 or 2 for Parts 2 and 3. Exclusion Criteria: - Prior treatment with or exposure to DR5 agonists. - Receipt of any anticancer therapy (including investigational agents) within 4 weeks or within 5 half-lives prior to the first dose of study treatment. Exceptions per protocol. - Receipt of radiotherapy within 4 weeks prior to the first dose of study treatment, and liver-directed within 12 months prior to the first dose of study drug. - Subject has undergone allogeneic hematopoietic stem cell or bone marrow transplantation within the last 5 years. Exception: Participants who have had a stem cell or bone marrow transplant > 5 years ago are eligible for enrollment, as long as there are no symptoms of graft-versus-host disease (GVHD). - Prior or concurrent malignancies. Exception: Subjects with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessments of INBRX-109. - Hematologic malignancies. - Symptomatic active primary CNS tumors, leptomeningeal disease, and CNS metastases. Exceptions per protocol. - Chronic liver disease including but not limited to cirrhosis, non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH), alcohol-related liver disease, hemochromatosis, Wilson's disease, alpha-1 antitrypsin deficiency, multiple liver hemangioma (except incidental finding of clinically nonsignificant liver hemangioma), hepatic or biliary autoimmune disorders (ie, primary biliary cholangitis, autoimmune hepatitis), history of portal or hepatic vein thrombosis, and sinusoidal occlusion syndrome. Exceptions per protocol. - Acute viral or toxic liver disease within 12 months prior to the first dose of study drug. - Evidence or history of hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection. - Clinically significant cardiac condition, including myocardial infarction, uncontrolled angina, cerebrovascular accident, or other acute uncontrolled heart disease < 3 months; - Sensitivity or contraindications to INBRX-109, irinotecan, or temozolomide. - Major surgery within 4 weeks prior to enrollment on this trial. - Systemic infection requiring antibiotics within 2 weeks prior to the first dose of study drug. - Pregnant or nursing females. - Patients who are receiving strong cytochrome P450 (CYP) 3A inhibitors and/or inducers, and/or UGT1A1 inhibitors within 14 days of Cycle 1 Day 1. |
Country | Name | City | State |
---|---|---|---|
United States | University of Michigan | Ann Arbor | Michigan |
United States | Emory University - Winship Cancer Institute | Atlanta | Georgia |
United States | University of Colorado Hospital | Aurora | Colorado |
United States | Center for Cancer Research at NCI | Bethesda | Maryland |
United States | The University of Chicago | Chicago | Illinois |
United States | Cleveland Clinic | Cleveland | Ohio |
United States | City of Hope | Duarte | California |
United States | NEXT Oncology - Virginia | Fairfax | Virginia |
United States | START Midwest Michigan, PC | Grand Rapids | Michigan |
United States | UT MD Anderson Cancer Center | Houston | Texas |
United States | Valkyrie Clinical Trials | Los Angeles | California |
United States | Vanderbilt University School of Medicine | Nashville | Tennessee |
United States | David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center | New York | New York |
United States | University of Pennsylvania Abramson Cancer Center | Philadelphia | Pennsylvania |
United States | Oregon Health & Science University | Portland | Oregon |
United States | NEXT Oncology | San Antonio | Texas |
United States | University of California, San Diego (UCSD) - Moores Cancer Center | San Diego | California |
United States | Sarcoma Oncology Center | Santa Monica | California |
United States | HonorHealth Research Institute | Scottsdale | Arizona |
Lead Sponsor | Collaborator |
---|---|
Inhibrx, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Anti-tumor activity of INBRX-109 | Tumor response will be determined by RECISTv1.1. | Up to 2 years | |
Primary | Frequency and severity of adverse events of INBRX-109 | Adverse events will be assessed and severity assigned by using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0. | Up to 2 years | |
Primary | Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of INBRX-109 | The MTD and/or RP2D of INBRX-109 will be determined. | Up to 2 years | |
Secondary | Area under the serum concentration time curve (AUC) of INBRX-109 | Area under the serum concentration time curve (AUC) of INBRX-109 will be determined. | Up to 2 years | |
Secondary | Immunogenicity of INBRX-109 | Frequency of ant-drug antibodies (ADA) against INBRX-109 will be determined. | Up to 2 years | |
Secondary | Maximum observed serum concentration (Cmax) of INBRX-109 | Maximum observed serum concentration (Cmax) of INBRX-109 will be determined. | Up to 2 years | |
Secondary | Trough observed serum concentration (Ctrough) of INBRX-109 | Trough observed serum concentration (Cmax) of INBRX-109 will be determined. | Up to 2 years | |
Secondary | Time to Cmax (Tmax) of INBRX-109 | Time to Cmax (Tmax) of INBRX-109 will be determined. | Up to 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04457258 -
68Ga-FAPi-46 PET/CT Scan in Imaging Patients With Sarcoma
|
Early Phase 1 | |
Recruiting |
NCT04986748 -
Using QPOP to Predict Treatment for Sarcomas and Melanomas
|
||
Completed |
NCT04474678 -
Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!")
|
N/A | |
Recruiting |
NCT05415098 -
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
Recruiting |
NCT04535713 -
GALLANT: Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced Sarcoma
|
Phase 2 | |
Completed |
NCT03521531 -
Burden and Medical Care of Sarcoma in Germany
|
||
Completed |
NCT02496520 -
Dendritic Cell-based Immunotherapy for Advanced Solid Tumours of Children and Young Adults
|
Phase 1/Phase 2 | |
Terminated |
NCT02054104 -
Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum
|
Phase 1/Phase 2 | |
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Active, not recruiting |
NCT04577014 -
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
|
Phase 1/Phase 2 | |
Completed |
NCT04052334 -
Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue Sarcoma
|
Phase 1 | |
Completed |
NCT01593748 -
A Phase II Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma
|
Phase 2 | |
Completed |
NCT00199849 -
NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine
|
Phase 1 | |
Recruiting |
NCT04367779 -
Research of Biomarkers of Response to Proton Beam Therapy in Pediatric and Adult Patients.
|
||
Completed |
NCT01879085 -
Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT04553692 -
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants With Relapsed, Refractory, or Newly Diagnosed Cancers
|
Phase 1 | |
Completed |
NCT01209598 -
PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma
|
Phase 2 | |
Completed |
NCT04553471 -
Palliative Lattice Stereotactic Body Radiotherapy (SBRT) for Patients With Sarcoma, Thoracic, Abdominal, and Pelvic Cancers
|
N/A | |
Withdrawn |
NCT04906876 -
A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas
|
Phase 2 |